drugset
drugset / Trial / NCT04869358

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

NCT04869358 ↗

Phase 4 Completed 34 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation of ofatumumab treatment or at least 4 weeks after commencing ofatumumab treatment.

Timeline

Start
2021-05-27
Primary completion
2022-05-10
Completion
2023-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofatumumab Monoclonal antibody 20 mg Subcutaneous

Indications

multiple sclerosis